A Phase 3, Multicenter Study to Assess the Long-Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia

Trial Profile

A Phase 3, Multicenter Study to Assess the Long-Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 May 2017

At a glance

  • Drugs Olanzapine/samidorphan (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Alkermes plc
  • Most Recent Events

    • 22 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top